Download PDF
Horm Metab Res 1992; 24(3): 115-118
DOI: 10.1055/s-2007-1003271
Clinical

© Georg Thieme Verlag, Stuttgart · New York

The Effect of Etomoxir on Insulin Sensitivity in Type 2 Diabetic Patients

A. Hübinger1 , G. Weikert1 , H. P. O. Wolf2 , F. A. Gries1
  • 1Diabetes-Forschungsinstitut Düsseldorf, Universität Düsseldorf, Düsseldorf
  • 2Byk Gulden, Pharmaceuticals, Konstanz, Germany
Further Information

Publication History

1991

1991

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Oral application of 50 mg Etomoxir caused a significant rise (33.1 %) of insulin-mediated glucose uptake. This was shown in a placebo-controlled, double-blind randomized study in 8 type 2 diabetic patients by using the euglycemic clamp technique.

The mean metabolic clearance rate of glucose (MCR) was raised from 4.1±0.9 mg/(kg·min) to 5.4±1.2 mg/(kg·min) (x±SEM, P = 0.039). Plasma levels of free fatty acids (FFA), glucose counterregulatory hormones, lipids and C-peptide values during the clamps were not different after verum and placebo. We conclude that Etomoxir improves insulin sensitivity in type 2 diabetic patients.

Key words

CPTI-Inhibitor - Insulin Resistence - Type 2 Diabetes Mellitus - Etomoxir

      >